Висока важливість
31 жовт. 2026 р.
These findings indicate that polidocanol sclerotherapy might be a promising and safe treatment option for managing frequent nosebleeds in patients with HHT, which can significantly impact their quality of life. Patients may wish to discuss this treatment option with their healthcare providers.
This study aimed to see how effective polidocanol sclerotherapy is in treating nosebleeds in individuals with Hereditary Hemorrhagic Telangiectasia (HHT).
Patients reported a significant reduction in nosebleeds, decreasing from an average of 8.3 episodes per week to 2.35 episodes. Approximately 85% of the patients experienced at least a 50% reduction in the frequency of their nosebleeds, and 95% expressed a willingness to undergo the treatment again due to positive feelings about it.
Researchers examined 20 adults who underwent this treatment in a hospital between March 2022 and December 2025. They gathered data on the frequency of nosebleeds, any complications that arose, and patients' satisfaction with the treatment.
This study involved a small sample size and was observational, meaning it did not account for all possible influencing factors. Additionally, it included a retrospective review over a limited timeframe, so the long-term effects of the treatment are yet to be determined.
Для вашого лікаря:
PMID: 42966812
DOI: 10.1007/s00405-026-10780-1
Показано англійською
PURPOSE: Hereditary haemorrhagic telangiectasia (HHT) is frequently associated with recurrent epistaxis, causing morbidity and impaired quality of life. Data on operating room-based endonasal polidocanol sclerotherapy remain limited. This study aimed to assess the effectiveness, safety, patient acceptance, and procedural feasibility of this approach for HHT-related epistaxis. METHODS: A retrospective observational study was conducted in a tertiary referral centre including 20 adults with HHT treated with endonasal polidocanol sclerotherapy between March 2022 and December 2025. Clinical variables, visceral arteriovenous malformation (AVM) involvement, procedure-related variables, complications, and patient-reported outcomes were analysed. RESULTS: A total of 59 procedures were performed. Mean weekly epistaxis frequency decreased from 8.3 to 2.35 episodes per week (p < 0.001), with a mean relative reduction of 68.1% and an effect size of 1.27. Seventeen patients (85%) met responder criteria, defined as a reduction of at least 50% in weekly epistaxis frequency compared with baseline. Fourteen patients (70%) presented visceral AVM involvement, and 35% had high-burden disease. Severe epistaxis episodes requiring hospital-based care showed a non-significant numerical decrease. Two patients (10%) experienced complications, one requiring hospital admission. Nineteen patients (95%) reported willingness to undergo the procedure again. CONCLUSION: Operating room endonasal polidocanol sclerotherapy was associated with clinically meaningful reduction in epistaxis burden, high patient acceptance, and a favourable safety profile. This approach may represent a valuable option for selected patients with recurrent HHT-related epistaxis requiring structured management beyond an office-based setting.